1. Home
  2. SOPH vs CCCC Comparison

SOPH vs CCCC Comparison

Compare SOPH & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$8.34

Market Cap

462.3M

Sector

Health Care

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.98

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOPH
CCCC
Founded
2011
2015
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
404.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SOPH
CCCC
Price
$8.34
$2.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$7.50
★ $12.20
AVG Volume (30 Days)
624.7K
★ 1.8M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
$23.09
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$3.75
$1.69
52 Week High
$8.98
$5.17

Technical Indicators

Market Signals
Indicator
SOPH
CCCC
Relative Strength Index (RSI) 57.08 27.04
Support Level $4.63 $2.52
Resistance Level $8.84 $3.20
Average True Range (ATR) 0.40 0.17
MACD -0.04 -0.05
Stochastic Oscillator 68.38 16.37

Price Performance

Historical Comparison
SOPH
CCCC

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: